EU drug agency approves extra Pfizer-BioNTech shots
EU regulator concludes that 3rd dose raises antibody levels if administered 6 months after second vaccine
The EMA’s Committee for Human Medicine assessed data on Pfizer-BioNTech booster shots and concluded that it showed “a rise in antibody levels when a booster dose is given approximately six months after the second dose in people from 18 to 55 years old,” the EU regulator said in a statement.
It did not directly advise a third dose for healthy adults.
The scientific body is still evaluating data on Moderna booster shots.
Pfizer-BioNTech vaccines were the first COVID-19 jabs authorized in the European Union, and the bloc financially contributed to the development of the vaccine under an advanced purchase agreement signed in 2020.
This year, Pfizer-BioNTech committed to delivering a total of 600 million vaccine doses to the bloc.
The vaccine is based on messenger RNA (mRNA), a messenger molecule with instructions to produce a protein from the virus that causes COVID-19 to prepare the body to fight the disease.
Contrary to traditional vaccines, Pfizer-BioNTech’s jab does not contain the virus itself.